Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2008-01-08
2008-01-08
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C435S455000, C435S325000, C435S069100, C536S024100
Reexamination Certificate
active
07316923
ABSTRACT:
The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. The invention also provides methods for isolation of nucleic acid molecules (particularly cDNA molecules) encoding a variety of proteins, including transmembrane proteins, and for isolation of cells expressing such transmembrane proteins which may be heterologous transmembrane proteins. The invention also is directed to isolated genes, gene products, nucleic acid molecules, to compositions comprising such genes, gene products and nucleic acid molecules, and to vectors and host cells comprising such genes and nucleic acid molecules, that may be used in a variety of therapeutic and diagnostic applications. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.
REFERENCES:
patent: 5707830 (1998-01-01), Calos
patent: 5728551 (1998-03-01), Devine et al.
patent: 5733761 (1998-03-01), Treco et al.
patent: 5783385 (1998-07-01), Treco et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5830698 (1998-11-01), Reff et al.
patent: 5843772 (1998-12-01), Devine et al.
patent: 6136566 (2000-10-01), Sands et al.
patent: 6270989 (2001-08-01), Treco et al.
patent: 6361972 (2002-03-01), Harrington et al.
patent: 71893/94 (1994-06-01), None
patent: 0 742 285 (1996-11-01), None
patent: 2 707 091 (1995-01-01), None
patent: WO93/09222 (1993-05-01), None
patent: WO94/12650 (1994-06-01), None
patent: WO95/31560 (1995-11-01), None
patent: WO96/04391 (1996-02-01), None
patent: WO96/29411 (1996-09-01), None
patent: WO98/14614 (1998-04-01), None
patent: WO99/07389 (1999-02-01), None
patent: WO99/15650 (1999-04-01), None
patent: WO99/50426 (1999-10-01), None
US 5,733,746, 03/1998, Treco et al. (withdrawn)
Palmer et al.; Genetically modified skin fibroblast persist long after transplantation but gradually inactivate introduced genes 1991, Proc. Natl. Acad. Sci. vol. 88: 1330-1334.
Riddell et. al.; T-cell mediated rejection of gene-modified HIV-specific cytotoxic T Lymphocytes in HIV-infected patients, 1996 Nature Medicine, vol. 2. No. 2: 216-223.
Verma et al.; Gene therapy-promises. problems and prospects. 1997, Nature vol. 389: 239-242.
Dang et. al.; Gene Therapy and Translational Cancer Research, 1999. Clinical Cancer Research vol. 5 471-474.
Lehninger et al., The introns transcribed into RNA are removed by splicing, 1997, Principles of Biochemistry, p. 867.
Barker, C.S., et al., “Activation of the Prolactin Receptor Gene by Promoter Insertion in a Moloney Murine Leukemia Virus-Induced Rat Thymoma,”J. Virol. 66(11):6763-6768 (1992).
Black, A.C., et al., “HTLV-II Rex Binding and Activity Requires an Intact Splice Donor Site and a Specific RNA Secondary Structure,”AIDS Res.&Human Retroviruses 8:870 (1992).
Brikun, I., et al., “Analysis of CRP-CytR Interactions at theEscherichia coliudp Promoter,”J. Bacteriology 178(6):1614-1622 (Mar. 1996).
Buckler, A.J., et al., “Exon amplification: A strategy to isolate mammalian genes based on RNA splicing,”Proc. Natl. Acad. Sci. USA 88:4005-4009 (1991).
Butturini, A., et al., “Oncogenes in Human Leukemias,”Acta Haematologica 78(suppl. 1):2-10 (1987).
Butturini, A., and Gale, R.P., “Oncogenes and Human Leukemias,”Intl. J. Cell Cloning 6(1):2-24 (1988).
Chakraborty, A.K., et al., “Transforming function of proto-ras genes depends on heterologous promoters and is enhanced by specific point mutations,”Proc. Natl. Acad. Sci. USA 88:2217-2221 (1991).
Chang, W., et al., “Enrichment of Insertional Mutants Following Retrovirus Gene Trap Selection,”Virol. 193:737-747 (1993).
Chow, W.-Y., and Berg, D.E., “Tn5tac1, a derivative of transposon Tn5 that generates conditional mutations,”Proc. Natl. Acad. Sci. USA 85:6468-6472 (1988).
Church, D.M., et al., “Isolation of genes from complex sources of mammalian genomic DNA using exon amplification,”Nature Genetics 6:98-105 (1994).
Crabb, B.S., and Cowman, A.F., “Characterization of promoters and stable transfection by homologous and nonhomologous recombination inPlasmodium falciparum,” Proc. Natl. Acad. Sci. USA 93:7289-7294 (Jul. 1996).
Datson, W.A., et al., “Specific isolation of 3'-terminal exons of human genes by exon trapping,”Nucl. Acids Res. 22(20):4148-4153 (1994).
Datson, W.A., et al., “Scanning for genes in large genomic regions: cosmid-based exon trapping of multiple exons in a single product,”Nucl. Acids Res. 24: 1105-1111 (Mar. 1996).
De Benedetti, A., and Rhoads, R.E., “A novel BK virus-based episomal vector for expression of foreign genes in mammalian cells,”Nucl. Acids Res. 19:1925-1931 (1991).
Dickson, C., et al., “Tumorigenesis by Mouse Mammary Tumor Virus: Proviral Activation of a Cellular Gene in the Common Integration Regionint-2,” Cell 37:529-536 (1984).
Dostatni, H., et al., “Use of Retroviral Vectors for Mapping of Splice Sites in Cottontail Rabbit Papillomavirus,”J. Gen. Virol. 69:3093-3100 (1988).
Duesberg, P.H., et al., “Cancer Genes by Non-Homologous Recombination,” In:Boundaries between Promotion and Progression during Carcinogenesis, Sudilovsky, O., et al., eds., Plenum Press, New York, NY, pp. 197-211 (1991).
Duyk, G.M., et al., “Exon trapping: A genetic screen to identify candidate transcribed sequences in cloned mammalian genomic DNA,”Proc. Natl. Acad. Sci. USA 87:8995-8999 (1990).
Frankel, W., et al., “Retroviral insertional mutagenesis of a target allele in a heterozygous murine cell line,”Proc. Natl. Acad. Sci. USA 82:6600-6604 (1985).
Fujisawa, J.-I., et al., “Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor,”Proc. Natl. Acad. Sci. USA 82:2277-2281 (1985).
Fung, Y.-K.T., et al., “Activation of the Cellular Oncogene c-erb8 by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus,”Cell 33:357-368 (1983).
Goff, S.P., “Gene Isolation by Retroviral Tagging,”Meth. Enzymology 152:469-481 (1987).
Hayward, W.S., et al., “Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis,”Nature 290:475-480 (1981).
Jackson, I.J., “A reappraisal of non-consensus mRNA splice sites,”Nucl. Acids Res. 19(14):3795-3798 (1991).
Joshi, S., “A Putative Approach for Cloning ‘Silent’ Genes Using Retroviral Vectors,”Med. Hypoth. 36:242-245 (1991).
Joyner, A.L., “Gene Targeting and Gene Trap Screens Using Embryonic Stem Cells: New Approaches to Mammalian Development,”BioEssays 13:649-656 (1991).
Junejo, F., et al., “Sequence analysis of the herpes simplex
Harrington John J.
Rundlett Stephen
Sherf Bruce
Athersys, Inc.
Guzo David
Lahive & Cockfield LLP
Nguyen Quang
LandOfFree
Compositions and methods for non-targeted activation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for non-targeted activation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for non-targeted activation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2807631